Newer parameters of the octreotide test in patients with acromegaly.

IF 3.3 2区医学 Q2 ENDOCRINOLOGY & METABOLISM Pituitary Pub Date : 2024-02-01 Epub Date: 2023-11-24 DOI:10.1007/s11102-023-01362-z

Shin Urai, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Hidenori Fukuoka, Michiko Takahashi, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa

{"title":"Newer parameters of the octreotide test in patients with acromegaly.","authors":"Shin Urai, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Hidenori Fukuoka, Michiko Takahashi, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa","doi":"10.1007/s11102-023-01362-z","DOIUrl":null,"url":null,"abstract":"Purpose: Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs.Methods: In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate.Results: The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma.Conclusion: The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pituitary","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11102-023-01362-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs.

Methods: In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate.

Results: The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma.

Conclusion: The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肢端肥大症患者奥曲肽试验的新参数。

目的:预测第一代生长抑素受体配体(fg-SRLs)的治疗效果对于评估或规划肢端肥大症患者的有效治疗策略非常重要。常用的奥曲肽试验的最大生长激素抑制率参数具有次优的预测值。因此，本研究探索了奥曲肽试验预测长效fg- srl治疗效果的新参数。方法:采用单中心回顾性研究方法，对2008年4月至2023年3月连续45例treatment-naïve肢端肥大症患者的奥曲肽试验参数及3个月时fg-SRL的治疗效果进行研究。此外，还探讨了奥曲肽试验参数与fg- srl治疗效果的关系。根据大腺瘤纵向直径的变化来评估肿瘤的缩小程度。计算生长激素抑制面积-曲线下时间(AUC)和达到生长激素最低点所需时间，并与最大生长激素抑制率进行比较。结果:AUC估计血清胰岛素样生长因子I的减少和肿瘤缩小。在大腺瘤患者中，GH降至最低水平的时间比GH的最大抑制率更能预测肿瘤的缩小。结论:AUC和GH降至最低点的时间可能是奥曲肽试验评估fg- srl治疗效果的新参数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pituitary 医学-内分泌学与代谢

CiteScore

7.10

自引率

7.90%

发文量

审稿时长

6 months

期刊介绍： Pituitary is an international publication devoted to basic and clinical aspects of the pituitary gland. It is designed to publish original, high quality research in both basic and pituitary function as well as clinical pituitary disease. The journal considers: Biology of Pituitary Tumors Mechanisms of Pituitary Hormone Secretion Regulation of Pituitary Function Prospective Clinical Studies of Pituitary Disease Critical Basic and Clinical Reviews Pituitary is directed at basic investigators, physiologists, clinical adult and pediatric endocrinologists, neurosurgeons and reproductive endocrinologists interested in the broad field of the pituitary and its disorders. The Editorial Board has been drawn from international experts in basic and clinical endocrinology. The journal offers a rapid turnaround time for review of manuscripts, and the high standard of the journal is maintained by a selective peer-review process which aims to publish only the highest quality manuscripts. Pituitary will foster the publication of creative scholarship as it pertains to the pituitary and will provide a forum for basic scientists and clinicians to publish their high quality pituitary-related work.